S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

$17.13
-0.69 (-3.87 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$16.65
Now: $17.13
$17.46
50-Day Range
$13.11
MA: $14.70
$17.83
52-Week Range
$4.51
Now: $17.13
$18.38
Volume247,900 shs
Average Volume315,939 shs
Market Capitalization$633.28 million
P/E RatioN/A
Dividend YieldN/A
Beta3.33
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.28 million
Book Value$2.75 per share

Profitability

Net Income$-30,290,000.00
Net Margins-289.90%

Miscellaneous

Employees68
Market Cap$633.28 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.


Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) announced its earnings results on Monday, August, 12th. The biotechnology company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The biotechnology company earned $5.45 million during the quarter, compared to the consensus estimate of $6 million. Molecular Templates had a negative return on equity of 44.86% and a negative net margin of 289.90%. View Molecular Templates' Earnings History.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Molecular Templates.

What price target have analysts set for MTEM?

2 equities research analysts have issued twelve-month price objectives for Molecular Templates' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Molecular Templates' share price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 29.9%. View Analyst Price Targets for Molecular Templates.

What is the consensus analysts' recommendation for Molecular Templates?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

Press coverage about MTEM stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Molecular Templates earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Molecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,260,000 shares, an increase of 10.5% from the December 31st total of 1,140,000 shares. Based on an average daily volume of 348,800 shares, the short-interest ratio is presently 3.6 days. Approximately 5.7% of the company's shares are sold short. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Alibaba Group (BABA), SLS International (SLS) and ACADIA Pharmaceuticals (ACAD).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (9.08%), Perceptive Advisors LLC (6.69%), FMR LLC (1.31%), Sectoral Asset Management Inc (1.17%), Parkman Healthcare Partners LLC (0.92%) and Geode Capital Management LLC (0.79%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Institutional Ownership Trends for Molecular Templates.

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including AXA, BVF Inc. IL, Goldman Sachs Group Inc., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Molecular Templates.

Which major investors are buying Molecular Templates stock?

MTEM stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Parkman Healthcare Partners LLC, Monashee Investment Management LLC, Abingworth LLP, Sectoral Asset Management Inc, Man Group plc and EAM Investors LLC. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Insider Buying and Selling for Molecular Templates.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $17.13.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $633.28 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.View Additional Information About Molecular Templates.

What is Molecular Templates' official website?

The official website for Molecular Templates is http://www.mtem.com/.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]


MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  589
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel